Business

Milestone Pharmaceuticals has raised $55 million in a Series C financing round led by Novo Holdings A/S, the company said. The company plans to use the money to fund Phase 3 clinical development of etripamil, an intranasal calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia (PSVT). Earlier this year, Milestone announced positive … [Read more...] about Milestone Pharmaceuticals raises $55 million for development of intranasal etripamil

Dewmar International says that it has filed a provisional patent application titled "Cannabinoid Formulation to Treat Lung Cancer" with the United States Patent and Trademark Office (USPTO). The companies current brands include "Kush Cakes" psychedelic brownies and "Canna Energy" hemp drinks. According to Dewmar, "The invention relates to an inhalation … [Read more...] about Dewmar International files provisional patent application for inhaled cannabinoid lung cancer therapy

Perrigo announced that it has settled Hatch-Waxman litigation brought by Meda Pharmaceuticals and Cipla regarding Dymista azelastine HCl/fluticasone propionate nasal spray. Meda's NDA for Dymista was approved by the FDA for the treatment of allergic rhinitis in 2012. Meda was acquired by Mylan in 2016. Perrigo Executive VP and President, Rx Pharmaceuticals, … [Read more...] about Perrigo settles litigation related to Dymista nasal spray

Sunovion has announced that it has agreed to divest US rights to the Alvesco ciclesonide MDI for the treatment of asthma and the Omnaris and Zetonna ciclesonide nasal sprays for the treatment of allergic rhinitis to Covis Pharma. The company acquired the US rights to the products from Takeda in 2008 and launched Alvesco and Omnaris that same year. Zetonna, an HFA … [Read more...] about Sunovion divests US rights to its ciclesonide aerosol products to Covis Pharma

During a July 11, 2017 meeting between AstraZeneca CEO Pascal Soriot and Australian Prime Minister Malcolm Turnbull, Soriot announced an A$100 million expansion of the company's manufacturing facility in Sydney, which he called "really a center of excellence for us, for the manufacture of inhaler products for the treatment of asthma and COPD." The Sydney facility … [Read more...] about AstraZeneca to invest A$100 million to expand Pulmicort Respules plant in Australia

Vectura subsidiary Jagotec has entered into a development and license deal with Sandoz for its VR2081 combination therapy MDI for the treatment of asthma and COP, the company announced. Sandoz will pay $5 million up front and up to an additional $5 million in milestone payments, plus royalties on net sales, for US rights to the product. According to Vectura, … [Read more...] about Vectura licenses VR2081 MDI to Sandoz

According to Spyryx Biosciences, Cystic Fibrosis Foundation Therapeutics (CFFT) will increase a development award to Spyryx to provide a total of up to $5 million. The company said that it plans to use the funds for its HOPE-1 Phase 2 study of SPX-101, an inhaled SPLUNC1-derived peptide, in CF patients. Earlier this year, Spyryx announced positive top line data … [Read more...] about Spyryx Biosciences gets additional funding for development of SPX-101 for CF

Consort Medical, parent company of device manufacturer Bespak and CDMO Aesica, has announced that its pre-tax profits for fiscal year 2017 almost doubled from FY 2016, rising from £11.3 million to £21.9 million. Bespak earnings before interest and taxes (EBIT) rose 3.9% and Aesica's EBIT rose 17.7%. Consort acquired Aesica in 2014, and in November 2015, the … [Read more...] about Consort Medical doubles pre-tax profit over previous fiscal year